Brief: Hansoh Pharmaceutical Says Phase III Clinical Study Of HS-20093 Has Met Primary Endpoint
28/07/2026 16:19
BRIEF-Hansoh Pharmaceutical Says Phase III Clinical Study Of HS-20093 Has Met Primary Endpoint July 28 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK:
PHASE III CLINICAL STUDY OF HS-20093 IN TREATMENT- OF OSTEOSARCOMA HAS MET PRIMARY ENDPOINT
TO INITIATE BIOLOGICS LICENSE APPLICATION PROCESS IN CHINA IN THE NEAR TERM
Further company coverage: 3692.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion